Researchers restore communication between lab grown neurons in promising MND study

A collaborative group of researchers has made important findings that can help us better understand how a common characteristic of motor neuron disease (MND) damages nerve cells, and how this damage could potentially be prevented. This month they published a paper outlining their research showing how correcting a specific problem involving a gene called UNC13A could restore communication between neurons affected by faulty TDP-43.

Using antisense oligonucleotides (ASOs), small fragments of genetic material that have seen success in treating SOD-1 and FUS genetic forms of MND, the researchers were able to correct the problem involving UNC13A and restore communication in lab grown motor neurons. 

The findings provide evidence that targeting UNC13A could be a promising approach for further research into developing treatments for MND. 

In 2023, this research was highlighted as part of the “Turning the Tide” documentary, the production of which was partially funded by MND Scotland, alongside other charities such as LifeArc. The short documentary details the scientific discovery and shares first-hand the impact on the lives of people living with the disease and their hopes for ongoing research in the field. 

What is TDP-43 and what happens when it is faulty?

TDP-43 is a protein that is normally found in the cell nucleus and helps neurons process genetic instructions. These instructions are used by cells to produce other protein that they need to function. 

In about 95–97% of cases of MND, TDP-43 becomes faulty. The faulty TDP-43 protein moves out of the nucleus and forms clumps in other areas of the cell. This means that it can no longer carry out its normal role properly and these mislocated clumps can also be toxic to neurons. 

One of the genes affected by TDP-43 not working properly is called UNC13A. It carries instructions for making a protein involved in the communication between neurons. TDP-43 not working properly means the instructions for producing this UNC13A protein are processed incorrectly, meaning less working UNC13A protein is produced to help the neurons communicate. 

What did the researchers do? 

The researchers developed specific small molecules called antisense oligonucleotides (ASOs) targeting UNC13A. The ASO binds to and acts upon a specific area of the genetic instruction that is causing the problem in making the protein. The ASO stops an unwanted section of genetic instruction, which disrupts the productions of working UNC13A protein, from being included in the production process. 

In this study, the ASO was tested in lab grown motor neurons. They found that treatment with the ASO improved the cell’s ability to create working UNC13A protein. They also noted that correcting the UNC13A production improved the ability of the neurons to communicate. 

Neurons communicate by releasing and receiving chemical signals at an area called the synapse. In MND, this ability to communicate decreases and is lost as the disease progresses. This study has shown that correcting UNC13A production improved the release of these chemical signals, helping restore neuron communication. 

What do these findings mean?

TDP-43 is involved in many processes in the neurons, affecting hundreds of genes. This makes it a challenge to identify which changes faulty TDP-43 causes are most important in MND and might be targets for potential treatments. 

An encouraging finding from this study was that communication between neurons was restored by correcting the problem TDP-43 caused with UNC13A. This suggests that the loss of working UNC13A protein, caused by faulty TDP-43, plays an important role in the neuron’s communication issues. Restoring some of this function is a step forward in helping to understand how we may be able to manage or prevent this damage to neurons. 

What could this mean for future MND research?

The research is still at an early stage. The researchers have not yet shown that correcting UNC13A can prevent loss of motor neurons or slow the disease progression. There is also further work needed to understand the other changes caused by TDP-43 in MND and how correcting UNC13A might influence these. 

However, the findings of this study are an important step forward in helping us better understand MND and show that UNC13A is a potential treatment target worth further investigation. There is a phase one/two trial, FUNCtion ALS led by Trace Neuroscience and taking place in Germany, the Netherlands and the UK (London and Sheffield), exploring the use of an ASO targeting UNC13A. The ASO being tested in this trial is different to the one the researchers used in their study, although both are designed to target UNC13A.  

FUNCtion ALS will initially look at whether the treatment is safe to give to people, how the ASO behaves in the human body, and will also look for any early signs of benefit. If the results of the phase one/two trial show the treatment to be safe and appropriate for further testing, a phase three clinical trial would need to be carried out to investigate if it can slow disease progression or provide other benefits to people with MND. 

This research has given more understanding of how faulty TDP-43 can affect neuronal communication in MND and has shown that some of these effects can be resolved in lab models. While more research is still needed before the findings of this research could potentially benefit people living with MND, they provide us with a positive avenue for potential future treatment targets. 

Further information 

Published paper in Nature – UNC13A splice correction rescues synaptic dysfunction induced by TDP-43 loss | Nature 

Information on FUNCtion ALS trial – FUNCtion ALS: Aiming to Restore UNC13A Function in People Living With ALS

Latest news

Sign up
for newsletter

Get the latest news and events straight to your inbox.

Step 1 of 2

Name(Required)
Which newsletters would you like to receive(Required)

You can help create a world without MND

Before you go

Please consider donating to help make time count for people affected by MND.